Allogene Therapeutics (ALLO) Change in Account Payables (2018 - 2026)

Allogene Therapeutics has reported Change in Account Payables for 9 years, with the latest figure at $663000.0 in Q1 2026.

• Quarterly Change in Account Payables rose 297.32% year-over-year to $663000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$232000.0 (up 67.82% YoY) and the FY2025 annual result came in at -$1.2 million, down 144.73% from the prior year.
• Change in Account Payables advanced to $663000.0 in Q1 2026 per ALLO's latest filing, from $599000.0 in the prior quarter.
• Over five years, Change in Account Payables peaked at $6.8 million in Q2 2024 and troughed at -$7.2 million in Q3 2024.
• A 5-year average of -$217941.2 and a median of -$118000.0 in 2024 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2025: Change in Account Payables plunged 491.61% in 2023, then surged 1661.76% in 2025.
• Over 5 years, Change in Account Payables stood at $2.9 million in 2022, then slumped by 110.28% to -$302000.0 in 2023, then surged by 111.26% to $34000.0 in 2024, then soared by 1661.76% to $599000.0 in 2025, then advanced by 10.68% to $663000.0 in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered $663000.0, $599000.0, and -$1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.